CN114073766A - Helicobacter pylori epitope peptide and application thereof - Google Patents
Helicobacter pylori epitope peptide and application thereof Download PDFInfo
- Publication number
- CN114073766A CN114073766A CN202011384410.2A CN202011384410A CN114073766A CN 114073766 A CN114073766 A CN 114073766A CN 202011384410 A CN202011384410 A CN 202011384410A CN 114073766 A CN114073766 A CN 114073766A
- Authority
- CN
- China
- Prior art keywords
- peptide
- epitope
- helicobacter pylori
- yolk antibody
- dendritic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention provides a helicobacter pylori epitope peptide, application thereof in preparing a yolk antibody and an anti-helicobacter pylori yolk antibody, and provides a new means for preventing and treating helicobacter pylori infection-related diseases.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to helicobacter pylori epitope peptide and application thereof.
Background
Helicobacter pylori (h. pylori) belongs to gram-negative bacillus, has a high infection rate, and can cause gastritis, gastric ulcer and even gastric cancer. Only a small fraction of infected individuals develop clinical symptoms, while most asymptomatic carriers are overlooked, indirectly leading to widespread helicobacter pylori transmission among the population. Diseases caused by h.pyri infection have been treated mainly by triple combination, i.e., by adding two antibiotics to a proton pump inhibitor, but this method has drawbacks of antibiotic resistance, large side effects, high recurrence rate, and the like. Therefore, it is necessary to develop new methods for preventing and treating h.
The egg yolk antibody (immunoglobulin yolk, IgY) is immunoglobulin which exists in the blood of a hen and can be transferred to the egg yolk of the hen and plays a role in protecting the hen during and after the incubation of the hen, is also the only immunoglobulin in the egg yolk, and has good stability, high permeability resistance, heat resistance, acid resistance and alkali resistance. The yolk antibody is prepared without sacrificing immunized animals, and the antibody can be continuously produced, so the method is suitable for industrial popularization and application.
The design of single epitope multiple antigenic peptide (SEA-MAP) can collect high concentration effective antigenic epitope in a smaller space range, so that the immunogenicity is greatly enhanced compared with that of linear antigenic peptide. The invention designs specific single epitope B cell antigen peptide aiming at helicobacter pylori, the antigen peptide has good immunogenicity, SEA-MAP is creatively prepared on the basis of the high-specificity single epitope antigen peptide, the SEA-MAP replaces the traditional linear peptide antigen to immunize poultry animals, a yolk antibody with stronger specificity is obtained, and a foundation is laid for preparing medicines or preparations for preventing and treating the helicobacter pylori.
Disclosure of Invention
The invention aims to provide a helicobacter pylori single epitope antigen peptide, which comprises any one or combination of KNLIGDKANS (SEQ ID NO: 1), LPALKENNGTVN (SEQ ID NO: 2), QAINPDNLTGS (SEQ ID NO: 3), RSRYSELGNTY (SEQ ID NO: 4), HAFIKSSFFNSA (SEQ ID NO: 5), DKATNFLGKNN (SEQ ID NO: 6), SKKKGSDHAA (SEQ ID NO: 7) and YYSFMGAELK (SEQ ID NO: 8).
Another objective of the invention is to provide a dendritic epitope peptide with a structure shown in a formula I,
wherein, X is basic amino acid, and Z is helicobacter pylori single epitope antigen peptide.
In a preferred embodiment of the present invention, the basic amino acid is selected from any one of arginine (R), lysine (K), and histidine (H).
In a preferred embodiment of the present invention, the single epitope antigenic peptide is selected from any one of KNLIGDKANS (SEQ ID NO: 1), LPALKENNGTVN (SEQ ID NO: 2), QAINPDNLTGS (SEQ ID NO: 3), RSRYSELGNTY (SEQ ID NO: 4), HAFIKSSFFNSA (SEQ ID NO: 5), DKATNFLGKNN (SEQ ID NO: 6), SKKKGSDHAA (SEQ ID NO: 7), YYSFMGAELK (SEQ ID NO: 8) or a combination thereof.
Another objective of the invention is to provide an application of the single epitope peptide or the dendritic epitope peptide in preparing a medicament for preventing and/or treating diseases related to helicobacter pylori infection.
In a preferred embodiment of the present invention, the disease is selected from any one of acute gastritis, chronic gastritis, peptic ulcer, gastric cancer, atrophic gastritis, gastric cancer, and gastric mucosa-associated lymphoid tissue lymphoma, or a combination thereof.
In a preferred embodiment of the present invention, the peptic ulcer is selected from any one of gastric ulcer, duodenal ulcer, esophageal ulcer, gastrojejunostomy ulcer, and Meckel diverticular ulcer of gastric mucosa, or a combination thereof.
The invention also aims to provide a preparation method of the yolk antibody, which comprises the following steps: the egg yolk antibody is prepared by immunizing poultry with the single epitope antigen peptide or the dendritic epitope peptide.
In a preferred embodiment of the present invention, the avian animal is selected from any one of chicken, duck, goose and bird, or a combination thereof.
In a preferred technical scheme of the invention, the method comprises the following steps: s1: adopting the single epitope antigen peptide or the dendritic epitope peptide to immunize poultry animals to prepare a yolk antibody;
s2: and (5) extracting and purifying the yolk antibody.
In a preferred embodiment of the present invention, S1 includes the steps of:
(1-1) selecting female poultry animals, mixing the single epitope antigen peptide or the dendritic epitope peptide with Freund's complete adjuvant in equal volume, fully emulsifying, and performing multi-point injection on the breast muscle and the root of thigh of the animals at the immune dose of 1 ml/animal;
(1-2) boosting immunization once every two weeks by using the immunogen obtained by isovolumetrically mixing and fully emulsifying the single epitope antigen peptide or the dendritic epitope peptide and Freund's incomplete adjuvant, wherein the immunization dose is 1 ml/mouse, and the boosting immunization is preferably carried out for at least 3 times;
(1-3) collecting eggs 2 weeks after the last booster immunization, preferably collecting eggs for at least 2 months.
In a preferred embodiment of the present invention, non-immunized eggs are collected as negative control.
In a preferred embodiment of the present invention, S2 includes the steps of:
(2-1) removing the poisoned eggs, collecting yolk and puncturing, measuring 10ml of yolk liquid, adding 10 times of double distilled water for dilution, uniformly mixing, adjusting the pH to 4-5, standing overnight at-20 ℃, thawing at room temperature, centrifuging at 12000rpm at 4 ℃ for 30min, filtering the supernatant by using filter paper for degreasing, collecting the supernatant, adding ammonium sulfate to enable the final concentration to be 20%, standing for 1h, centrifuging at 12000rpm at 4 ℃ for 15min, and collecting precipitates;
(2-2) dissolving the precipitate in 20ml of 0.01M PBS (pH7.4), adding ammonium sulfate to a final concentration of 14%, standing for 1h, centrifuging at 12000rpm at 4 ℃ for 15min, and dissolving the collected precipitate in 2ml of 0.01M PBS (pH7.4); stirring and dialyzing in double distilled water for 1 hr, changing dialysate for 1 time, dialyzing overnight, collecting dialyzed supernatant, filtering with 0.22 μm filter membrane for sterilization, and storing at-20 deg.C in sterile EP tube.
In a preferred embodiment of the invention, the dialysis fluid is exchanged 2 to 5 times, preferably 3 to 4 times.
The invention also aims to provide the yolk antibody prepared by the method.
The invention also aims to provide the application of the single epitope antigen peptide or the dendritic epitope peptide in preparing the yolk antibody.
The invention also aims to provide application of the yolk antibody in preparing a product for preventing and/or treating diseases related to helicobacter pylori infection.
In a preferred technical scheme of the invention, the product is selected from any one of medicines, health products, functional foods and special medical purpose formula Foods (FSMP) or a combination thereof.
In a preferred technical scheme of the invention, the medicine is selected from any one of tablets, capsules, granules, oral liquid, suspension, pills, powder, dripping pills, syrup, mixture, lotion, effervescent agent, emulsion and tea or the combination thereof.
In the preferred technical scheme of the invention, the health care product is selected from any one of drinks, soup, tea, wine, bee products, fresh juice and medicated diet or the combination of the drinks, the soup, the tea, the wine, the bee products, the fresh juice and the medicated diet.
Unless otherwise indicated, when the present invention relates to percentages between liquids, said percentages are volume/volume percentages; the invention relates to the percentage between liquid and solid, said percentage being volume/weight percentage; the invention relates to the percentages between solid and liquid, said percentages being weight/volume percentages; the balance being weight/weight percent.
Compared with the prior art, the invention has the following beneficial technical effects:
1. the invention designs and screens out the high immunogenicity single epitope antigen peptide of helicobacter pylori, which can induce and generate high specificity antibody aiming at the helicobacter pylori.
2. The single epitope multiple antigenic peptide (SEA-MAP) is prepared based on the screened single epitope antigenic peptide, the design of the dendritic epitope peptide can increase the molecular weight and the biological activity of the antigenic peptide, so that the orientation of the connected epitope peptide has consistency, the specific binding capacity and the reaction sensitivity of the epitope peptide are exponentially increased in unit space, and the induction production of a high-titer specific antibody is facilitated.
3. The SEA-MAP immune avian animal prepared by the helicobacter pylori single epitope antigen peptide obtains the high specificity yolk antibody, has high inhibition rate on the helicobacter pylori, is beneficial to large-scale industrial production, and provides a new means for preventing and treating the helicobacter pylori infection related diseases.
Detailed Description
The principles and features of this invention are described below in conjunction with specific embodiments, the examples given are intended to illustrate the invention and are not intended to limit the scope of the invention.
EXAMPLE 1 preparation of yolk antibody
Selecting 20-week-old hens, and mixing the amino acid sequences shown in SEQ ID NO: 1-8, mixing the single epitope antigen peptide with Freund's complete adjuvant in equal volume, emulsifying, and injecting into breast muscle and thigh root of hen at dosage of 1 ml/chicken; every two weeks, the immunogen which is obtained by isovolumetrically mixing and fully emulsifying the single epitope antigen peptide or the dendritic epitope peptide and Freund incomplete adjuvant is adopted for boosting immunization once, the immunization dose is 1 ml/one immunogen, and the boosting immunization is carried out for 3 times; eggs were collected 2 weeks after the last booster immunization, while non-immunized eggs were collected as negative controls.
Removing the poisoned eggs, collecting yolk and puncturing, measuring 10ml of yolk liquid, adding 10 times of double distilled water for dilution, uniformly mixing, adjusting the pH value to 4-5, standing overnight at-20 ℃, thawing at room temperature, centrifuging at 12000rpm at 4 ℃ for 30min, filtering the supernatant with filter paper for degreasing, collecting the supernatant, adding ammonium sulfate to make the final concentration 20%, standing for 1h, centrifuging at 12000rpm at 4 ℃ for 15min, and collecting the precipitate; dissolving the precipitate in 20ml 0.01M PBS (pH7.4), adding ammonium sulfate to make the final concentration to be 14%, standing for 1h, centrifuging at 4 deg.C at 12000rpm for 15min, and dissolving the collected precipitate in 2ml 0.01M PBS (pH7.4); stirring and dialyzing in double distilled water for 1 hr, changing dialysate for 1 time, 4-5 times, dialyzing overnight, collecting dialysate, filtering with 0.22 μm filter membrane for sterilization, and storing at-20 deg.C in sterile EP tube. The titers of the yolk antibodies obtained by using different antigen peptides were determined by ELISA method, and the results are shown in Table 1.
TABLE 1
| Linear single epitope antigenic peptide | Yolk antibody titer |
| Negative control | —— |
| SEQ ID NO：1 | 1:512 |
| SEQ ID NO：2 | 1:1024 |
| SEQ ID NO：3 | 1:1024 |
| SEQ ID NO：4 | 1:256 |
| SEQ ID NO：5 | 1:1024 |
| SEQ ID NO：6 | 1:512 |
| SEQ ID NO：7 | 1:1024 |
| SEQ ID NO：8 | 1:1024 |
Example 2 preparation of yolk antibody
Hens of 20 weeks of age were selected and will be based on SEQ ID NO: 1-8 by solid phase synthesis, the dendritic epitope peptide was mixed with Freund's complete adjuvant in equal volume and emulsified thoroughly, and then hens were immunized according to the method of example 1 and purified yolk antibody was extracted. The titer of the yolk antibody obtained by using different dendritic epitope peptides is measured by an ELISA method, and the result is shown in Table 2.
TABLE 2
| Numbering | Dendritic epitope peptides | Yolk antibody titer |
| 1 | Negative control | —— |
| 2 | Formula I, wherein X ═ R, Z ═ SEQ ID NO: 1 | 1:6400 |
| 3 | Formula I, wherein X ═ R, Z ═ SEQ ID NO: 2 | 1:6400 |
| 4 | Formula I, wherein X ═ R, Z ═ SEQ ID NO: 3 | 1:12800 |
| 5 | Formula I, wherein X ═ R, Z ═ SEQ ID NO: 4 | 1:3200 |
| 6 | Formula I, wherein X ═ R, Z ═ SEQ ID NO: 5 | 1:25600 |
| 7 | Formula I, wherein X ═ R, Z ═ SEQ ID NO: 6 | 1:3200 |
| 8 | Formula I, wherein X ═ R, Z ═ SEQ ID NO: 7 | 1:12800 |
| 9 | Formula I, wherein X ═ R, Z ═ SEQ ID NO: 8 | 1:6400 |
Example 3 Bactericidal Effect of yolk antibody against helicobacter pylori
Helicobacter pylori (H.pylori) SS1 strain in BHIIn the culture solution, in a three-gas incubator (O)2 5％，CO2 15％，N285 percent), culturing for 72 hours at 37 ℃ until the colony concentration reaches 109After each ml, 1mg of the yolk antibody of example 2 Nos. 4, 6 and 8 was added to 1ml of the bacterial suspension, mixed and incubated for 1 hour, the bacterial suspension was spread on BHI agar medium, cultured for 48 hours under the above conditions to count colonies, and the inhibition rate was calculated.
Bovine serum albumin was used as a blank control instead of the yolk antibody, and another common oral bacterium, Staphylococcus aureus, was used as a negative control (LB medium, 37 ℃, 5% CO)2Culture). The results are shown in Table 3.
TABLE 3
| Group of | Cell inhibition (%) |
| H.pylori | 0 |
| S.aureus | 0 |
| H.pylori+BSA | 4 |
| Yolk antibody No. 4 of pylori + | 82 |
| Yolk antibody of H.pyri +6 | 88 |
| Yolk antibody No. 8 of pylori + | 78 |
| S.aureus+BSA | 2 |
| Egg yolk antibody No. S.aureus +4 | 3 |
| Egg yolk antibody S.aureus +6 | 1 |
| Egg yolk antibody No. S.aureus +8 | 5 |
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (9)
1. A helicobacter pylori monoaxial antigenic peptide, characterized in that its amino acid sequence comprises SEQ ID NO: 1-8, or a combination thereof.
2. A dendritic epitope peptide comprising the monoepitope antigenic peptide of claim 1, wherein said dendritic epitope peptide has the structure of formula I:
wherein, X is basic amino acid, and Z is helicobacter pylori single epitope antigen peptide.
3. The dendroepitopic peptide of claim 2, wherein the basic amino acid is selected from any one of arginine (R), lysine (K), and histidine (H).
4. The dendritic epitope peptide of any one of claims 2 to 3, wherein the single epitope antigen peptide comprises the amino acid sequence of SEQ ID NO: 1-8, or a combination thereof.
5. Use of the single epitope antigenic peptide of claim 1 or the dendritic epitope peptide of claims 2-4 for the preparation of a medicament for the prevention and/or treatment of a disease associated with helicobacter pylori infection.
6. A method for preparing an egg yolk antibody is characterized by comprising the following steps: a yolk antibody is prepared by immunizing an avian animal with the mono-epitope antigen peptide or the dendritic epitope peptide according to claims 1 to 4.
7. A yolk antibody produced by the method of claim 6.
8. Use of the mono-epitope or dendritic epitope peptide of claims 1-4 for the preparation of a yolk antibody.
9. Use of the egg yolk antibody according to claim 7 in the preparation of a product for the prevention and/or treatment of a disease associated with helicobacter pylori infection.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010837770 | 2020-08-19 | ||
| CN2020108377707 | 2020-08-19 | ||
| CN202011098086 | 2020-10-14 | ||
| CN2020110980868 | 2020-10-14 | ||
| CN202011096949 | 2020-10-14 | ||
| CN2020110969498 | 2020-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114073766A true CN114073766A (en) | 2022-02-22 |
Family
ID=80282883
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011375035.5A Pending CN114073764A (en) | 2020-08-19 | 2020-11-30 | Toothpaste capable of efficiently inhibiting helicobacter pylori, preparation method and application thereof |
| CN202011377169.0A Pending CN114073765A (en) | 2020-08-19 | 2020-11-30 | Composition for inhibiting helicobacter pylori and application thereof |
| CN202011384410.2A Pending CN114073766A (en) | 2020-08-19 | 2020-11-30 | Helicobacter pylori epitope peptide and application thereof |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011375035.5A Pending CN114073764A (en) | 2020-08-19 | 2020-11-30 | Toothpaste capable of efficiently inhibiting helicobacter pylori, preparation method and application thereof |
| CN202011377169.0A Pending CN114073765A (en) | 2020-08-19 | 2020-11-30 | Composition for inhibiting helicobacter pylori and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN114073764A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020193295A1 (en) * | 2001-05-04 | 2002-12-19 | Emanuel Calenoff | Immunogenic peptides and uses thereof |
| CN106084008A (en) * | 2016-06-16 | 2016-11-09 | 江苏安泰生物技术有限公司 | For HPV infection being carried out tree-shaped polypeptide and screening technique, the preparation method and application of cell therapy |
| CN106119195A (en) * | 2016-06-16 | 2016-11-16 | 江苏安泰生物技术有限公司 | A kind of for inducing the test kit and abductive approach producing the DC cell identifying HPV |
| CN108794628A (en) * | 2018-05-28 | 2018-11-13 | 广东工业大学 | A kind of Yolk antibody preparation method and application of anti-helicobacter pylori |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101214279A (en) * | 2008-01-09 | 2008-07-09 | 浙江工商大学 | Method for extracting flavone and polysaccharide from mulberry leaf |
| KR20100043882A (en) * | 2008-10-21 | 2010-04-29 | 김정환 | Extract of mulberry leaves having inhibition activity for helicobacter pylori, method for preparing the same and the healthfunctional food using thereof |
| CN104387447A (en) * | 2011-03-25 | 2015-03-04 | 江苏安泰生物技术有限公司 | DC cell-based hepatitis B virus T epitope peptide |
| CN106075436B (en) * | 2016-07-12 | 2020-01-03 | 闫小君 | An oral preparation containing no antibiotic for resisting helicobacter pylori |
| CN108670931A (en) * | 2018-07-24 | 2018-10-19 | 冯绍良 | A kind of toothpaste and its production method for capableing of suppressing and killing helicobacter pylori |
| CN110025714A (en) * | 2019-04-26 | 2019-07-19 | 曾文华 | A kind of preparation method of oral spray that preventing and treating Helicobacter pylori infection |
| CN110393216A (en) * | 2019-08-13 | 2019-11-01 | 江苏安泰生物技术有限公司 | A kind of anti-helicobacter pylori health food and preparation method thereof |
| CN110507583A (en) * | 2019-09-27 | 2019-11-29 | 江苏协合转化医学研究院有限公司 | A kind of efficient prevention and control helicobacter pylori fresh breath toothpaste and preparation method thereof |
-
2020
- 2020-11-30 CN CN202011375035.5A patent/CN114073764A/en active Pending
- 2020-11-30 CN CN202011377169.0A patent/CN114073765A/en active Pending
- 2020-11-30 CN CN202011384410.2A patent/CN114073766A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020193295A1 (en) * | 2001-05-04 | 2002-12-19 | Emanuel Calenoff | Immunogenic peptides and uses thereof |
| CN106084008A (en) * | 2016-06-16 | 2016-11-09 | 江苏安泰生物技术有限公司 | For HPV infection being carried out tree-shaped polypeptide and screening technique, the preparation method and application of cell therapy |
| CN106119195A (en) * | 2016-06-16 | 2016-11-16 | 江苏安泰生物技术有限公司 | A kind of for inducing the test kit and abductive approach producing the DC cell identifying HPV |
| CN108794628A (en) * | 2018-05-28 | 2018-11-13 | 广东工业大学 | A kind of Yolk antibody preparation method and application of anti-helicobacter pylori |
Non-Patent Citations (5)
| Title |
|---|
| BUGAYTSOVA, J.A.等: "Hop family adhesin BabA [Helicobacter pylori]", GENBANK登录号：WP_108169269.1, pages 1 - 2 * |
| JESPERSEN M.C.等: "BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes", NUCLEIC ACIDS RESEARCH, vol. 45, pages 24 * |
| 孙礼进 等: "抗幽门螺杆菌多价蛋白液IgY抗体的制备", 细胞与分子免疫学杂志, vol. 34, no. 6, pages 555 - 560 * |
| 徐晨静 等: "幽门螺杆菌外膜蛋白及其毒力的研究进展", 实用临床医药杂志, vol. 24, no. 9, pages 127 - 132 * |
| 薛利军 等: "幽门螺杆菌VacA、CagA及BabA蛋白的二级结构和免疫表位预测分析", 中国免疫学杂志, vol. 27, pages 1153 - 1158 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114073765A (en) | 2022-02-22 |
| CN114073764A (en) | 2022-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102037885B1 (en) | Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications | |
| AU2010319047A1 (en) | Therapeutic agent for psoriasis or atopic dermatitis | |
| JPH0657663B2 (en) | Method for producing multifunctional specific antibody | |
| US20020044942A1 (en) | Transfer factor composition and process for producing same | |
| KR100221452B1 (en) | Preparation for vaccine composition against enteric infection | |
| CN104606675A (en) | Preparation method of poultry multi-linked specific egg yolk antibodies and transfer factors | |
| CN109400705A (en) | A kind of anti-helicobacter pylori duck Yolk antibody and preparation method thereof | |
| CN103906760A (en) | Human lactoferrin derived peptide for use as an antigen masking agent | |
| CN109453372A (en) | A kind of additive of the Yolk antibody of duck containing anti-helicobacter pylori | |
| CN100412092C (en) | Bacillus coli resisting chicken yolk antibody, its preparation and use | |
| CN114073766A (en) | Helicobacter pylori epitope peptide and application thereof | |
| KR100267746B1 (en) | Oral immunological preparation containing egg-yolk antibodies, for prevention and treatment of porcine diarrhea caused by enterotoxigenic escherichia coli | |
| CN111748042B (en) | African swine fever fusion protein containing endotoxin and preparation method and application thereof | |
| CN109608541B (en) | Yolk antibody for resisting swine enterotoxigenic escherichia coli and preparation method thereof | |
| CN111793137A (en) | Hp tetravalent antigen and preparation method and application thereof | |
| Henning | Calf paratyphoid II. Artificial immunization | |
| WO2021087441A2 (en) | Composition and methods for preventing and treating african swine fever in wild and domestic swine | |
| WO2013004020A1 (en) | Pseudomonas aeruginosa (pa-msha) strain igy and preparation method and use thereof | |
| KR100338922B1 (en) | A producing method of conjugate specific immunoprotein against five species of microbes inducing gastritis and duodenal ulcer | |
| TWI511743B (en) | Antiserum, neutralizing antibody, and pharmaceutical composition containing the same | |
| CN111263639A (en) | Compositions, methods of preparation and evaluation of complex immunogens named I-SPGA for the production of Immunologically Active Proteins (IAPs) | |
| Megha et al. | Generation and Characterization of specific Chicken Egg Yolk Antibodies (IgY) against microbial bio-terroristic Agent (Vibrio cholerae) | |
| CN111825774B (en) | Bivalent LTB toxin of porcine pathogenic escherichia coli as well as preparation process and application thereof | |
| US20080102067A1 (en) | Immunogenic composition | |
| KR100573424B1 (en) | Immune milk containing Helicobacter pylori antibody ? its manufacturing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |